DelveInsight Blog
C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum’s Poziotinib; Orphan Drug Designation to Tenaya’s Gene Therapy; EC Approves Regeneron’s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer
C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...
Find MoreSign Up & Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Join Up Now!Editor's Pick
Newsletter/Whitepaper
-Agonist.png "Toll-like Receptors Agonist")
Sign up For Newsletters
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
Recent Article
ASCO Conference 2022
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.
